(Q35737080)

10 August 2017

1 reference

title

Drug-induced pleural disease. (English)

1 reference

10 August 2017

John T Huggins

1

1 reference

10 August 2017

Steven A Sahn

series ordinal

2

1 reference

10 August 2017

publication date

1 March 2004

1 reference

Clinics in Chest Medicine

10 August 2017

published in

1 reference

10 August 2017

volume

25

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

141-153

1 reference

Drug-induced pleural disease

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

1 reference

7 January 2021

Pericardial Disorders Occurring During Open-Label Study of 1,869 Severely Hypertensive Patients Treated with Minoxidil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleuropericardial effusion associated with minoxidil administration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Interstitial pulmonary fibrosis: a new side effect of practolol.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Letter: practolol-induced pleurisy and constrictive pericarditis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleural fibrosis after practolol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Respiratory disease associated with practolol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Progressive pleural thickening during oxprenolol therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pulmonary toxicity of amiodarone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Amiodarone pulmonary toxicity: CT findings in symptomatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Amiodarone pulmonary toxicity presenting as bilateral exudative pleural effusions

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Amiodarone pneumonitis: three further cases with a review of published reports

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Lung disease caused by amiodarone, a new antiarrythmic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Amiodarone pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pneumonitis after amiodarone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Amiodarone pulmonary toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: a possible complication of a new antiarrhythmic drug

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Amiodarone pulmonary toxicity. Chest radiography and CT in asymptomatic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Low-dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Development of pleural effusion after sclerotherapy with absolute alcohol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Cardiac and pulmonary fibrosis during methysergide therapy for headache

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Fibrotic Disorders Associated with Methysergide Therapy for Headache

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleural effusion and fibrosis secondary to Sansert administration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleural effusion and fibrosis during treatment with methysergide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleural thickening caused by Sansert and Ergotrate in the treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleuropulmonary disease associated with dopamine agonist therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleuropulmonary involvement during bromocriptine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pulmonary complications associated with combination chemotherapy programs containing bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Factors influencing postoperative morbidity and mortality in patients treated with bleomycin.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Bleomycin hypersensitivity pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Hypersensitivity to procarbazine (Matulane®) manifested by fever and pleuropulmonary reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

1 reference

7 January 2021

Methotrexate-induced pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Methotrexate Therapy and Pulmonary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleurisy and methotrexate treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Methotrexate therapy and pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Severe pneumonitis occurring during methotrexate therapy. Re- port of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Interstitial pneumonia from mitomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Lung toxicity associated with cyclophosphamide use. Two distinct patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide. A case report

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Eosinophilic Pleural Effusion Associated With Valproic Acid Administration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Eosinophilic pleuritis due to propylthiouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Tuberculosis patients. Who should we isolate?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Isotretinoin and eosinophilic pleural effusion

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Drug-induced bronchopulmonary pleural disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Chronic nitrofurantoin pulmonary reaction. Report of 5 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Lymphopenia in acute nitrofurantoin pleuropulmonary reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleuropericardial Reaction to Treatment With Dantrolene

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleural effusion associated with chronic dantrolene administration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pneumonitis, pleural effusion and pericarditis following treatment with dantrolene

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Eosinophilic pleural effusion due to gliclazide

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Fever, pulmonary infiltrates, and pleural effusion following acyclovir therapy for herpes zoster ophthalmicus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Polyserositis associated with clozapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Cellulitis, eosinophilia, and unilateral pleural effusion associated with clozapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

D-Penicillamine Induced Goodpasture's Syndrome in Wilson's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Isolated pleural effusion with hematopoietic cells of mixed lineage in a patient receiving granulocyte-colony-stimulating factor after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Chest roentgenographic abnormalities in IL-2 recipients. Incidence and correlation with clinical parameters.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Development of pleural and pericardial effusions during itraconazole therapy of pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Clinical features in 20 patients and aspects of pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

L-tryptophan induced cough and pleural effusions associated with the eosinophilia-myalgia syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Acute eosinophilic pulmonary disease associated with the ingestion of L-tryptophan-containing products

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Hypersensitivity pneumonitis and pulmonary vasculitis with eosinophilia in a patient taking an L-tryptophan preparation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleuropericarditis related to the use of mesalamine

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Interstitial lung disease with pleural effusion caused by simvastin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Pleuropulmonary disease in a man with diabetes who was treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Recurrent lymphocytic pleural effusion after intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Lupus pleuritis. Clinical features and pleural fluid characteristics with special reference to pleural fluid antinuclear antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Drug-induced lupus: clinical spectrum and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2803%2900125-4

7 January 2021

10.1016/S0272-5231(03)00125-4

Identifiers

DOI

1 reference

release_qhv5mpbdafaitbhjowbg2u5yju

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qhv5mpbdafaitbhjowbg2u5yju

24 November 2022

mapped directly with Wikidata item

1 reference